T here is a growing body of information that suggests a pathophysiologic role of oxygen free radical-mediated lipid peroxidation in cerebral ischemia. One reported biochemical index of ischemia-induced oxygen radical formation and lipid peroxidation is a reduction in cerebral tissue concentrations of the endogenous antioxidants ascorbate, 1 -2 glutathione, 3 and a-tocopherol. 4 The reasonable assumption from these studies has been that tissue antioxidants are consumed in an attempt to quench ischemia-triggered free radical processes.
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More direct evidence for the occurrence of lipid peroxidation in cerebral ischemia has also been obtained. Watson et al 5 have shown in rats that brain conjugated diene content increases during a 30-minute period of severe forebrain ischemia and increases even more after reperfusion. The same group 6 has shown that vitamin E-depleted rats display more postischemic lipid peroxidation than vitamin E-enriched rats, with rats having normal vitamin E concentrations falling between. Very recently, Kirsch et al 7 have observed a postischemic change in the electron spin resonance spectrum of brain samples from rats pretreated with the oxygen free radical spin trap phenyl-f-butyl nitrone, clearly indicative of ischemic oxygen free radical generation.
However, the successful implication of oxygen free radical-mediated peroxidation as a causal factor in postischemic neuronai degeneration depends largely on a demonstration that pharmacologic treatments selectively directed at scavenging oxygen free radicals or inhibiting lipid peroxidation can exert a beneficial effect in models of cerebral ischemia. Toward this goal, Traystman and coworkers have documented a protective effect of the superoxide radical scavenger superoxide dismutase in cat models of both global 8 and focal 9 cerebral ischemia plus reperfusion. In both instances, superoxide dis-mutase improved postischemic cerebral blood flow and neurophysiologic recovery. Similarly, pretreatment with the more lipid soluble antioxidant vitamin E has also been shown to exert a beneficial effect in experimental cerebral ischemia.
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To further examine the role of oxygen free radical processes in the pathophysiology of cerebral ischemia, we investigated the ability of a novel 21-aminosteroid inhibitor of lipid peroxidation U74006F (21-[4-(2,6-di-l-pyrrolidinyl-4-pyrimidinyl)-l-piperazinyl]-16a-methylpregna-l ,4,9(1 l)-triene-3,20-dione, monomethane sulfonate) to protect against postischemic neuronal degeneration and mortality in gerbils following 3 hours of unilateral carotid artery occlusion. U74006F, while totally lacking in glucocorticoid or other steroid hormonal activities, 12 has been shown to be an extremely potent and effective inhibitor of iron-dependent lipid peroxidation in central nervous system (CNS) tissue in vitro. 13 Thus, U74006F provides an excellent pharmacologic tool with which to investigate the pathophysiologic involvement of oxygen free radicalinduced lipid peroxidation in a model of severe brain ischemia followed by reperfusion.
Materials and Methods

Induction of ischemia and reperfusion. Male
Mongolian gerbils (Meriones unguiculatus) weighing 55-65 g that were fed (Purina Rat Chow, Richmond, Indiana) and watered ad libitum were lightly anesthetized with methoxyflurane. A midline neck incision was made, the right carotid artery was isolated and clamped with a microaneurysm clamp, and the incision was closed with wound clips. The gerbils were then placed in individual cages for recovery and observed for signs of ischemia including circling, torso curvature, inability to walk, ptosis, barrel rolling, opisthotonos, loss of righting reflex, running fits, and seizures.
14 Gerbils that did not show at least two of these signs by 1 hour after carotid clamping were eliminated from the study. After 3 hours, the gerbils were briefly anesthetized again with methoxyflurane, the clamps were removed, and the carotid arteries were visually examined to confirm reperfusion. The neck incisions were then sutured with silk thread.
Drug treatment. Gerbils were treated intraperitoneally with either vehicle (0.05N HC1) or U74006F (3 or 10 mg/kg); the injection volume was 0.2 ml. One injection was administered 10 minutes before carotid clamping and a second injection was given immediately after clamp removal. All studies were conducted in a blind and randomized fashion.
Survival studies (Series I). The first series of studies was carried out to ascertain the possible effect of U74006F on survival 24 and 48 hours after the 3-hour carotid artery occlusion. After clamp removal and the second injection of vehicle (23 gerbils), 3 mg/kg U74006F (14 gerbils), or 10 mg/kg U74006F (15 gerbils), the gerbils were 
FIGURE 1. Effects of U-74006F on 24-and 48-hour survival of male gerbils after 3-hour unilateral carotid artery occlusion. There were 23 gerbils treated with vehicle (V), 14 treated with 3 mg/kg U-74006F (3), and 15 treated with 10 mg/kg U-74006F (10). Probability values were derived from Cochrane's Q test.
housed in individual cages with food and water. Differences in 24-and 48-hour survival between the three treatment groups were analyzed by Cochrane's Q test, withp<0.05 being required for significance.
Histopathologic studies (Series 2).
A second series of studies was carried out to examine the effects of 10 mg/kg i.p. x2 U74006F (19 gerbils) compared with vehicle (22 gerbils) on 24-hour postischemic neuronal necrosis in the hippocampal CA, subfield and the medial and lateral portions of the cerebral cortex. After the 3-hour unilateral carotid artery occlusion, the gerbils were anesthetized again with methoxyflurane and perfused intracardially with saline followed by a mixture of 10% formaldehyde, 10% glacial acetic acid, and 80% methanol. The fixed brains were removed and imbedded in paraffin. Five-micrometer-thick cross sections (1.4-3.0 mm posterior to the bregma) were mounted on glass slides (two per slide) and stained with cresyl violet. Normal-appearing cresyl violet-stained neurons were counted in the two adjacent sections and averaged. Cell densities were measured at x 320 magnification over a 315 fim length of the hippocampal CA, subfield and a 222 /um 2 area of both the medial and lateral cortex of the same sections. All cell counts were carried out blindly as to treatment group. Differences in mean cell densities were analyzed using Student's t test (two-tailed), with p<0.05 being required for significance. 
Results
Effects of U74006F on Postischemic Survival (Series 1)
U74006F pretreatment did not mask the clinical signs of ischemia during the 3-hour unilateral carotid artery occlusion. There was no difference in the incidence of ischemic manifestations between vehicle-and U74006F-treated gerbils. Among the vehicle-treated gerbils, 41.9% demonstrated ischemic signs during the occlusion compared with 35.0% of the 3 mg/kg U74006F-treated and 40.5% of the 10 mg/kg U74006F-treated gerbils. These figures are consistent with the published incidence of successful hemispheric infarction in young male gerbils following ipsilateral carotid artery ligation.
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Concerning the postischemic survival of those gerbils that showed definite signs of ischemia during occlusion, only 14 of 23 (60.9%) vehicle-treated gerbils were still alive 24 hours after occlusion compared with 11 of 14 (78.6%) 3 mg/kg U74006F-treated gerbils or 13 of 15 (86.7%) 10 mg/kg U74006F-treated gerbils. While there appeared to be a doserelated improvement in survival with U74006F at 24 hours, the effect was not significant (Figure 1) . However, by 48 hours, the vehicle-treated and 3 mg/kg U74006F-treated group survivals fell to 34.8% and 28.6%, respectively. In contrast, survival in the 10 mg/kg U74006F-treated group was 80.0% (p<0.02 compared with vehicle).
Effects of U74006F on Postischemic Neuronal Necrosis (Series 2)
In vehicle-treated gerbils, neuronal densities were reduced significantly in all three brain regions examined 24 hours after unilateral carotid artery occlusion (Table 1, Figure 2 ). Cell loss was particularly prominent in the hippocampal CA, subfield and lateral cortex (15.3% and 9.3% of the nonischemic side, respectively). Necrosis in the medial cortex, while more moderate (72.7% of the nonischemic side), was also significant.
In contrast, U74006F significantly reduced postischemic neuronal necrosis (i.e., increased neuronal density compared with vehicle-treated gerbils) in all three brain regions examined (Table 1, Figure 2) . Table 2 expresses the data in terms of the incidence of brains with ^50% neuronal preservation, which also shows a significant effect of U74006F to reduce postischemic neuronal necrosis. Figure 3 displays representative photomicrographs of the nonischemic and ischemic hemispheres of vehicle-treated and 10 mg/kg U74006F-treated gerbil brains 24 hours after a 3-hour unilateral carotid artery occlusion. 
Discussion Our results demonstrate that the 21-aminosteroid U74006F can significantly protect against postischemic brain damage. U74006F reduced mortality over 48 hours following a 3-hour period of unilateral carotid artery occlusion and attenuated 24-hour postischemic neuronal necrosis in both the hippocampal CA, subfield and the cerebral cortex. Considering that U74006F and related 21-aminosteroids are potent inhibitors of iron-dependent lipid peroxidation in CNS tissue, 13 the beneficial effects of this compound further supports lipid peroxidation as a pathophysiologic process in postischemic neuronal damage.
U74006F is an extremely potent inhibitor of lipid peroxidation in rat brain homogenates and purified brain synaptosomes, with IC J0 s ranging from 12.9 to 59.0 nM in the case of various iron-catalyzed lipid peroxidation systems. 13 The ability of U74006F to inhibit CNS tissue lipid peroxidation appears to involve multiple mechanisms including a vitamin E-like scavenging of lipid hydroperoxides 13 and a scavenging of superoxide anion (J.M. Braughler, unpublished observations).
In addition to its documented ability to inhibit CNS tissue lipid peroxidation, U74006F has been observed to block both lipid peroxidation-induced (ferrous chloride) and iodoacetate-induced release of arachidonic acid from cultured mouse pituitary cells. 12 Since potentially deleterious arachidonic acid metabolites (prostaglandin F 2a , thromboxane A 2 ) increase dramatically in gerbil brain tissue during postischemic reperfusion, 17 a reduction in CNS membrane arachidonic acid release may also be an anti-ischemic mechanism for U74006F. However, this may actually represent an additional lipid peroxidation inhibitory action since a major potential source of ischemia-induced oxygen free radical generation is the cyclooxygenase enzyme, which is responsible for the conversion of arachidonic acid to prostaglandins. 18 Conversely, ischemia-triggered release of membrane arachidonic acid may actually be the consequence of the formation of membrane lipid hydroperoxides. 19 Therefore, the attenuation of arachidonic acid release by U74006F may be either a primary effect or secondary to an inhibition of membrane lipid hydroperoxide formation. Further studies are needed to provide conclusive evidence of an in vivo effect of U74006F on lipid peroxidation and/or arachidonic acid release. Until such data are provided, other protective mechanisms cannot be excluded.
At a physiologic level, earlier experiments have shown that U74006F can ameliorate delayed postischemic cortical hypoperfusion in cats when administered 15 minutes after a 5-minute episode of near-complete global brain ischemia. 20 Together with the support of cortical blood flow (CBF) in that study, U74006F also promoted neurophysiologic recovery as judged by an enhanced return of the somatosensory evoked potential. This effect of U74006F to maintain CBF after transient severe ischemia may also relate to the antioxidant action of the compound. Other experiments in our laboratories have shown that chronic dietary vitamin E supplementation can also attenuate postischemic cerebral hypoperfusion, which supports the role for a lipid peroxidative process in the pathogenesis of the phenomenon. 21 Since postischemic cerebral hypoperfusion is also observed in gerbils as a pathophysiologic event following transient forebrain ischemia, 22 its possible attenuation by U74006F, as shown after global brain ischemia in cats, 22 may likewise contribute to the reduced mortality and neuronal necrosis in our current study. On the other hand, a direct protection of neurons may also be involved since U74006F effectively penetrates the blood-brain barrier (J.M. Braughler and E.D. Hall, unpublished observations).
A previous investigation has shown that an identical treatment protocol with large doses (60 mg/kg i.p. x2) of the glucocorticoid methylprednisolone can also promote survival of gerbils following 3 hours of unilateral carotid artery occlusion.
14 Since methylprednisolone and other glucocorticoids (e.g., prednisolone, dexamethasone) are known to be at least weak inhibitors of CNS tissue lipid peroxidation, 23 an inhibition of ischemia-induced lipid peroxidation has been purported to explain methylprednisolone's anti-ischemic properties. Our current study has demonstrated that U74006F, which is a more potent and efficacious inhibitor of lipid peroxidation, 13 is similarly more potent and effective as an anti-ischemic agent. Furthermore, U74006F's complete lack of glucocorticoid activity, or effect to elevate blood glucose levels, 12 predicts that it would be devoid of any propensity to exacerbate ischemia-induced brain lactic acidosis. For these reasons, U74006F may be a safer and better agent for the treatment of cerebral ischemia than classical glucocorticoid steroids. Additional studies are needed to fully evaluate the anti-ischemic utility and mechanism of action of U74006F and other 21-aminosteroids in this novel chemical series.
